Outcome of Pediatric Patients With Pulmonary Arterial Hypertension in the Era of New Medical Therapies

American Journal of Cardiology

Volumn 106, Issue 1, 2010, Pages 117-124

  van Loon, Rosa Laura E ^a   Roofthooft, Marcus T R ^a   Delhaas, Tammo ^b   van Osch Gevers, Magdalena ^c   ten Harkel, Arend D J ^d   Strengers, Jan L M ^e   Backx, Ad ^f   Hillege, Hans L ^a   Berger, Rolf M F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Center for Congenital Anomalies of the Heart   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; COUMARIN DERIVATIVE; CREATININE; DILTIAZEM; DIURETIC AGENT; NIFEDIPINE; PROSTACYCLIN; SILDENAFIL; URIC ACID;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ASSESSMENT; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; HEART INDEX; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCHOOL CHILD; SURVIVAL RATE; SYSTEMIC PULMONARY SHUNT; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL; WALKING;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INFANT; MALE; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDINS; RECEPTORS, ENDOTHELIN; TREATMENT OUTCOME;

EID: 77953559693     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.02.023     Document Type: Article

References (29)

1. Simonneau G., Robbins I.M., Beghetti M., Channick R.N., Delcroix M., Denton C.P., Elliott C.G., Gaine S.P., Gladwin M.T., Jing Z.C., Krowka M.J., Langleben D., Nakanishi N., and Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54 suppl (2009) S43-S54
2. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., Fishman A.P., Goldring R.M., Groves B.M., and Kernis J.T. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
3. Galie N., Torbicki A., Barst R., Dartevelle P., Haworth S., Higenbottam T., Olschewski H., Peacock A., Pietra G., Rubin L.J., Simonneau G., Priori S.G., Garcia M.A., Blanc J.J., Budaj A., Cowie M., Dean V., Deckers J., Burgos E.F., Lekakis J., Lindahl B., Mazzotta G., McGregor K., Morais J., Oto A., Smiseth O.A., Barbera J.A., Gibbs S., Hoeper M., Humbert M., Naeije R., and Pepke-Zaba J. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25 (2004) 2243-2278
4. Humbert M., Sitbon O., and Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 351 (2004) 1425-1436
5. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
6. Sitbon O., Humbert M., Nunes H., Parent F., Garcia G., Herve P., Rainisio M., and Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
7. Humpl T., Reyes J.T., Holtby H., Stephens D., and Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 111 (2005) 3274-3280
8. Maiya S., Hislop A.A., Flynn Y., and Haworth S.G. Response to bosentan in children with pulmonary hypertension. Heart 92 (2006) 664-670
9. Rosenzweig E.B., Ivy D.D., Widlitz A., Doran A., Claussen L.R., Yung D., Abman S.H., Morganti A., Nguyen N., and Barst R.J. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 46 (2005) 697-704
10. Yung D., Widlitz A.C., Rosenzweig E.B., Kerstein D., Maislin G., and Barst R.J. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 110 (2004) 660-665
11. van Loon R.L., Roofthooft M.T., Osch-Gevers M., Delhaas T., Strengers J.L., Blom N.A., Backx A., and Berger R.M. Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis. J Pediatr 155 (2009) 176-182
12. Barst R.J., Maislin G., and Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99 (1999) 1197-1208
13. Lammers A.E., Hislop A.A., Flynn Y., and Haworth S.G. The 6-minute walk test: normal values for children of 4-11 years of age. Arch Dis Child 93 (2008) 464-468
14. Chetta A., Zanini A., Pisi G., Aiello M., Tzani P., Neri M., and Olivieri D. Reference values for the 6-min walk test in healthy subjects 20-50 years old. Respir Med 100 (2006) 1573-1578
15. Stichting Kind en Groei (Dutch Growth Research Foundation), Rotterdam, The Netherlands. Growth Analyser 3.5. 2009. Available at: http://www.growthanalyser.org.
16. Galie N., Seeger W., Naeije R., Simonneau G., and Rubin L.J. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 43 suppl (2004) 81S-88S
17. Barst R.J., Ivy D., Dingemanse J., Widlitz A., Schmitt K., Doran A., Bingaman D., Nguyen N., Gaitonde M., and van Giersbergen P.L. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 73 (2003) 372-382
18. Dickinson M.G., Scholvinck E.H., Boonstra A., Vonk-Noordegraaf A., Snijder R.J., and Berger R.M. Low complication rates with totally implantable access port use in epoprostenol treatment of pulmonary hypertension. J Heart Lung Transplant 28 (2009) 273-279
19. Sandoval J., Bauerle O., Palomar A., Gomez A., Martinez-Guerra M.L., Beltran M., and Guerrero M.L. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 89 (1994) 1733-1744
20. Sandoval J., Bauerle O., Gomez A., Palomar A., Martinez Guerra M.L., and Furuya M.E. Primary pulmonary hypertension in children: clinical characterization and survival. J Am Coll Cardiol 25 (1995) 466-474
21. Hoeper M.M., Markevych I., Spiekerkoetter E., Welte T., and Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26 (2005) 858-863
22. van Loon R.L., Hoendermis E.S., Duffels M.G., Vonk-Noordegraaf A., Mulder B.J., Hillege H.L., and Berger R.M. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?. Am Heart J 154 (2007) 776-782
23. Clabby M.L., Canter C.E., Moller J.H., and Bridges N.D. Hemodynamic data and survival in children with pulmonary hypertension. J Am Coll Cardiol 30 (1997) 554-560
24. Galie N., Beghetti M., Gatzoulis M.A., Granton J., Berger R.M., Lauer A., Chiossi E., and Landzberg M. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114 (2006) 48-54
25. van Albada M.E., Loot F.G., Fokkema R., Roofthooft M.T., and Berger R.M. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Review 63 (2008) 321-327
26. Apostolopoulou S.C., Manginas A., Cokkinos D.V., and Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart 93 (2007) 350-354
27. Duffels M.G., Vis J.C., van Loon R.L., Nieuwkerk P.T., van Dijk A.P., Hoendermis E.S., Bruin-Bon R.H., Bouma B.J., Bresser P., Berger R.M., and Mulder B.J. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome. Am J Cardiol 103 (2009) 1309-1315
28. McLaughlin V.V., Sitbon O., Badesch D.B., Barst R.J., Black C., Galie N., Rainisio M., Simonneau G., and Rubin L.J. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 (2005) 244-249
29. Provencher S., Sitbon O., Humbert M., Cabrol S., Jais X., and Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 27 (2006) 589-595